Biomedical Catalyst (BMC)

The BMC offers funding to small and medium-sized enterprises (SMEs) looking to develop innovative solutions to healthcare challenges – technologies and processes that will help provide disease prevention and proactive management of health and chronic conditions; earlier and better detection and diagnosis of disease, leading to better patient outcomes; and treatments that either change underlying disease or offer potential cures. Interested? Feel free to contact us.

Eligibility and scope of the programme

All projects must be led by a UK-based SME, working alone or in collaboration with other businesses, research and third sector organisations.

Feasibility studies are for the exploration and evaluation of the commercial potential of innovative scientific ideas. Primer awards are to conduct a technical evaluation of ideas through to proof of concept. Early Stage awards go beyond this up to the point of being ready for clinical testing (but cannot include any of this), whilst Late Stage awards focus on human trials to take the innovation close to commercialisation. Project durations vary from up to 12 months for feasibility studies whilst late stage awards are for up to 3 years.


Funding awards vary depend on the stage, ranging from up to £200,000 for feasibility studies through to a maximum of £4,000,000 available for late stage awards. Funding levels of up to 70% are available depending on the stage of development and size of company.

Need help?

Please contact us for further information on the funding scheme, to discuss a project or how we can support you with an application.